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ABSTRACT | The proximity of immune cell aggregations to the vasculature is a hallmark of multiple sclerosis. 
Furthermore, it is widely accepted that inflammation is able to modulate the microcirculation. Until recently, the detection 
of cerebral blood perfusion changes was technically challenging, and perfusion studies in multiple sclerosis patients 
yielded contradictory results. However, new developments in fast magnetic resonance imaging have enabled us to image 
the cerebral hemodynamics based on the dynamic tracking of a bolus of paramagnetic contrast agents (dynamic 
susceptibility contrast). This review discusses the technical principles, possible pitfalls, and potential for absolute 
quantification of cerebral blood volume and flow in a clinical setting. It also outlines recent findings on inflammation 
associated perfusion changes, which are inseparable from pathological considerations in multiple sclerosis. 
KEYWORDS | Perfusion; Magnetic Resonance Imaging; Multiple Sclerosis; Inflammation; Blood–brain Barrier; Dynamic 
Susceptibility Contrast. 
 
1. Introduction 
One of the crucial stages in the evolution of a multiple 
sclerosis lesion is considered to be the disruption of the 
blood brain barrier (BBB) [1,2], leading to edema in the 
CNS by accumulation of plasma fluids. This process is 
believed to be initiated by autoreactive CD4+ 
lymphocytes which migrate into the CNS and start an 
inflammatory response. Although BBB breakdown – 
imaged as focal enhancement in T1- weightedMRI after 
gadolinium-DTPA(Gd-DTPA) injection – is the gold 
standard of lesion detection during the course of the 
disease, the deposition of contrast agent in the CNS has 
been shown to correlate only modestly with clinical 
disability. However, new imaging techniques, which allow 
more accuracy inmonitoring the disease evolution, 
provide evidence of tissue damage in the normal 
appearing white matter (NAWM) preceding the 
appearance of newcontrast-enhancing lesions. A 
decrease in magnetization transfer ratio (MTR) is 
described prior to enhancement, indicating a diminished 
ability for saturation exchange due to edema and 
inflammation [3,4]. Changes in the lipid spectra have 
been noted in magnetic resonance spectroscopy 
preceding lesions [5]. Similarly, subtle increases in the 
random water molecule motion reflecting alterations in 
tissue integrity were detected weeks before leakage of 
the BBB by means of diffusion weighted imaging [6]. 
However, local changes in blood flow, a major 
consequence of inflammation [7–9], have so far received 
little attention. Perfusion imaging has been performed in 
several other neurological diseases, such as stroke and 
different forms of dementia. Here, reduced perfusion 
parameters in several brain regions were linked to 
decreased metabolic activity secondary to 
neurodegeneration [10,11]. Although in multiple sclerosis 
only few perfusion studies have been published so far, 
findings of very early focal perfusion changes during the 
inflammatory phase of the disease [12], and of generally 
reduced grey matter perfusion in MSpatients compared to 
healthy controls [13] might indeed influence our 
understanding of the underlying disease processes, and 
could be important for future therapeutic considerations. 
 
 
 
2. In vivo perfusion measurements: 
Technical background and pitfalls 
Cerebral perfusion is defined as the volume of blood 
flowing through a given volume of tissue per unit of time 
[14]. It is comprised of three parameters: the cerebral 
blood flow (CBF), the cerebral blood volume (CBV), and 
the mean transit time (MTT). Although the first reports on 
human cerebral flow measurements using magnetic 
resonance imaging date back as far as 1970 [15], 
perfusion measurements have remained technically 
challenging. In 1988, a transient change in contrast after 
injection of lanthanide chelates (Gd-DTPA) into healthy 
rats was described and explained by susceptibility effects 
in the microenvironment [16]. Such microscopic gradients 
lead to fast dephasing of proton spins, and hence to a 
reduction in the transverse relaxation time (a decrease in 
T2/T2*), which can be detected as signal loss during the 
fast passage of a contrast agent through the tissue (first 
pass effect). This effect dominates over the simultaneous 
T1 relaxation enhancement and extends well beyond the 
intravascular compartment; it also affects the surrounding 
tissue even though nondiffusible tracers, such as Gd-
DTPA, remain strictly intravascular in the presence of an 
intact BBB [17]. 
Imaging the first pass effect of intravenously injected 
paramagnetic contrast agents with high temporal 
resolution is called Bolus Tracking or Dynamic 
Susceptibility Contrast Magnetic Resonance Imaging 
(DSC-MRI). It is the most commonly used method to 
investigate hemodynamic changes. Maps of CBV, CBF 
and MTT are calculated on the assumption of an 
approximately linear relationship between the 
concentration of the contrast agent in the tissue and the 
change in T2* relaxation rate. CBV is determined by 
integrating the tissue concentration time curve of each 
voxel, and CBF by the deconvolution of this curve with an 
arterial input function (AIF: the concentration of contrast 
agent in the feeding vessel to the volume of interest (VOI) 
at a given time) [18]. MTT, the average time required for a 
given particle of tracer to pass through the tissue, can be 
calculated by the central volume theorem MTT=CBV/CBF 
[19]. Due to the rapid bolus transit, fast imaging is 
required in order to capture the first pass of the bolus (e.g. 
repetition time (TR) b1.5 s). Rapid injection of the contrast 
agent followed by a saline flush is imperative to obtain a 
sharp input bolus to the tissue (e.g. N3 ml/s). Today, 
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the availability of fast imaging techniques such as epi-
planar imaging (EPI) allows us to obtain sequential 
images of the wash in and wash out phase of a tracer 
during the few seconds of bolus transit through the tissue. 
Until recently, its use in clinical studies was restricted due 
to a number of technical limitations, such as a relatively 
poor spatial resolution leading to partial volume effects 
[20], limited volume coverage, and a low signal-to-noise 
ratio (SNR). Increased gradient performance and higher 
field strengths made perfusion MRI feasible even in a 
routine clinical setting. However, some caveats should be 
taken into consideration. Since the tracer concentration 
cannot be measured directly by MRI, it must be measured 
indirectly through its effect on signal intensity. Therefore 
the concentration of the contrast agent in various tissue 
compartments must be known or estimated in order to 
derive hemodynamic parameters from dynamic tracer 
analyses. As vascular structure has a strong influence on 
flow, an accurate acquisition of the AIF is essential [21]. 
The AIF depends not only on the shape of the injected 
bolus but also on the cardiac output, the vascular 
geometry, and the cerebral vascular resistance [22,23]. 
Accordingly, the site of the AIF estimation should be 
chosen as close to the region of interest as possible. For 
the quantification of absolute CBF, the AIF must be 
deconvolved. Several model-dependent and model-
independent deconvolution methods have been assessed 
and discussed in the past [24–28], and were recently 
reviewed by Ostergaard [18]. The selection of an 
approach sufficiently reflecting the in vivo situation is 
necessary for the correct prediction of absolute CBF 
values [29]. 
In some pathologies, such as multiple sclerosis, a 
conspicuous artefact can be observed in case of 
permeable capillary walls due to the defective BBB, e.g. 
in contrast-enhancing lesions. Here, the above mentioned 
assumption of a negligible effect of the contrast agent 
influx on T1 do not hold true. Leakage into the tissue 
leads to an artificially low estimate of CBV. Haselhorst et 
al. described an algorithm which can be applied to correct 
for the leakage artefact by fitting a model function for the 
plasma concentration to the measured data [30]. 
 
3. Cerebral perfusion changes precede 
blood–brain barrier breakdown in MS 
Early measurements of global perfusion in multiple 
sclerosis using radioactive 133Xe [31], positron emission 
tomography (PET) [32], or single photon emission 
computed tomography (SPECT) techniques [33] suffered 
from a very low spatial resolution. Findings of a generally 
lower perfusion in MS patients compared to healthy 
individuals were contradicted by the demonstration of 
increased perfusion during the time of acute inflammation 
in an animal model of MS [34]. 
With the advent of modern MR imaging and 
postprocessing techniques, it became possible to 
differentiate alterations in cerebral perfusion more 
accurately. Rashid et al. reported a hypoperfusion in the 
grey matter tissue, particularly in the thalamus and the 
caudate nuclei, and an increase in white matter perfusion 
in comparison to healthy controls, applying a novel 
continuous arterial spin labelling (CASL) technique and a 
statistical parametric mapping analysis (SPM) [13]. 
Haselhorst et al. were among the first to investigate 
different MS lesion types in a cross-sectional study [30]. 
After application of an extended BBB leakage correction 
to the data, the authors found a significantly higher CBV in 
acute Gd-DTPA enhancing plaques and a lower CBV in 
T1 hypointense lesions in comparison to the NAWMand 
T1 isointense tissue. Similar results were shown in a study 
by Ge et al. [35]. Our own group presented the first 
longitudinal data on perfusion changes during the genesis 
of MS lesions [12]. We confirmed that acute plaques are 
increased in both CBF and CBV prior to contrast 
enhancement, and that decreased perfusion persists in 
those plaques that remained T1 hypointense after several 
weeks. To our surprise, hyperperfusion developed weeks 
before lesions became visible in T2 or T1 weighted 
images, and even before changes in diffusion 
measurements were detectable. This was the first in vivo 
evidence that alterations in cerebral perfusion occur very 
early during the development of MS lesions, preceding 
overt changes in BBB permeability, T2 relaxation and 
diffusion properties. Recently, Broom et al. published a 
study which confirmed our findings in a rodent model of 
multiple sclerosis (experimental autoimmune 
encephalomyelitis, EAE) [36]. By investigating an animal 
model, his group was able to correlate perfusion and 
diffusion MRI findings with histopathology. Interestingly, 
regions with increased perfusion before contrast 
enhancement corresponded to areas with vessel 
dilatation, but could not be correlated to marked leukocyte 
infiltration, which defines an early stage of the 
inflammatory response with very low levels of 
macrophages, TandB cells.Up to date, technical 
limitations restricted the minimal size of a lesion to be 
followed (e.g. 5– 7 mm) [12]. Future improvement in 
resolution may enable us to differentiate even smaller 
plaques and to predict their development based on the 
regional hyperperfusion. Thus, perfusion MRI might 
become a more sensitive tool for detecting the onset of 
inflammatory changes in MS than any other 
conventionally used MRI parameter. 
 
4. Pathophysiological considerations 
The close vicinity of evolving plaques to venules – 
demonstrated histologically in human brain tissue [37,38], 
by MRI [39] and in animal models [40,41] – in MS 
suggests that perfusion and inflammation share common 
pathophysiological mechanisms. However, their 
relationship is far from being completely understood. 
Research in this area has focused both on vasoactive 
properties of soluble substances / cytokines produced and 
released during inflammation and on changes in the 
cellular homeostasis in astrocytes. Altered endothelial cell 
function might be the common final pathway leading to 
changes in perfusion and BBB leakage. 
In one of the first perfusion studies in MS, changes in the 
blood supply during inflammation were attributed to a 
heightened glucose metabolism resulting from increased 
inflammatory cell activation [34]. Effective vasodilators 
such as nitric oxide (NO) and substance P (SP) 
presumably originate during brain inflammation [42,43]. 
SP-producing immune reactive cells were identified at the 
edge of both active and inactive MS lesions, suggesting 
that substance P may play a role in MS lesion 
development [42]. More recently, the effects of primary 
inflammatory cytokines were studied in several models of 
neuroinflammation. An increase in the permeability of the 
BBB and higher CBV were seen after intrathecal 
application of interleukin-1β [44]. On the other hand, a 
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reduction of the CBV was observed in response to direct 
intrastriatal injection of tumour necrosis factor-α (TNFα), 
possibly reflecting a later stage of inflammation in this 
model [45]. TNFa and interferon-γ (IFNγ) are known to 
rapidly induce cultured endothelial cells to synthesize 
tetrahydrobiopterin, a limiting cofactor for the endothelial 
NO synthetase (eNOS) converting L-arginine to NO and 
Lcitrullin, thereby increasing NO production by activating 
eNOS [46]. Only at later stages does TNFα diminish NO 
release by destabilizing eNOS transcripts [47] and by 
reducing protein kinase B mediated phosphorylation of 
eNOS [48]. Production of NO by the inducible NO 
synthetase (iNOS) has also been implicated in the 
pathogenesis of MS. In a rodent model of EAE, the 
expression of iNOS in the CNS correlated with the 
severity of the disease, which was reversed by treatment 
with antisense cDNA [49] or NO scavengers [50]. 
Expression of iNOS has been found in active 
demyelinating lesions of postmortem brain tissue [51]. 
Interestingly, elevated levels of NO, TNFα and interleukin-
10 were also described in the cerebral spinal fluid of MS 
patients [52]. 
In addition to NO and cytokine mediated changes in 
cerebral perfusion, disturbed glial cell homeostasis may 
contribute to a heightened susceptibility for vascular 
changes in MS patients. Recently, it was reported that a 
rise of calcium levels within astrocytes induces 
constriction of blood vessels and consequently reduces 
cerebral blood flow [53]. The absence or reduction of 
astrocytic factors causes BBB endothelial cells to carry a 
reduced number of mitochondria. A decreased 
mitochondrial content in endothelial cells in MS 
postmortem tissue is hypothesized to be a primary event 
in the disruption of the BBB [54]. 
On the other hand, early vascular endothelial cell 
activation was identified prior to cerebral parenchymal 
reaction and demyelination [55], which, in combination 
with discrete microglial activation and perivascular cellular 
infiltrates, is a frequent finding in postmortem tissue of MS 
patients [56]. Microglial activation coincided with 
abnormal endothelial tight junctions in active lesions and 
normal appearing white matter, leading to putatively open 
junctions in microscopically inflamed vessels [57]. Future 
studies will have to prove whether and which vascular 
factors in MS patients may facilitate the inflammatory 
process, and whether vascular vulnerability in our patients 
is a prerequisite for the initiation of the autoimmune 
cascade. 
 
5. Conclusion 
In recent years, MR imaging has gained increasing 
importance in the diagnosis and monitoring of disease 
activity in multiple sclerosis. While the correlates of a BBB 
disruption revealed by conventional imaging techniques 
are relatively well understood, little is known about the 
potentially even more devastating early and diffuse 
processes during the disease course. Alterations in tissue 
integrity, axonal loss and neuronal damage take place in 
the normal appearing white and grey brain matter, so far 
undetectable by conventional MRI techniques. Recent 
studies using Diffusion MRI (DTI), Magnetization Transfer 
Imaging (MTI), or Proton-Spectroscopy (HMRS) 
demonstrated that some of these changes are detectable 
already in the earliest phase of the disease, the clinical 
isolated syndrome, and that these precede the plaque 
development visualized by conventional MRI. Only a few 
studies have so far investigated the alterations of cerebral 
blood perfusion caused by inflammation. This might be 
due to technical difficulties in the past, which hindered 
sufficiently high spatial and temporal resolution, though 
these difficulties can be overcame today. Very recently it 
was shown that each inflammatory stage presents its own 
perfusion characteristics, e.g. hyperperfusion in the acute 
stage of a contrast enhancing lesion, or hypoperfusion in 
a chronic lesion with axonal loss. 
As discussed above, endothelial cell dysfunction occurs 
very early during the inflammatory cascade, and we 
observe hyperperfusion preceding overt changes in BBB 
permeability. Most intriguingly, these alterations in 
perfusion occur even before changes are detectable by 
any MR imaging technique, such as DTI, MTI, or HMRS. 
Thus, perfusion MRI may be used as a sensitive indicator 
of inflammatory activity. Little is known about the cause of 
early perfusion changes. Invading immune cells 
presumably stimulate the brain vascular endothelial cells. 
Additionally, histological studies point to endothelial 
abnormalities in MS patients. Future investigations of 
vasoactive components and the interaction of invading 
immune cells with the resident CNS milieu will increase 
the knowledge on the underlying disease process. 
Technical advances made in vivo perfusion imaging 
feasible even in a routine clinical setting, adding only 1 
min to the total scan time with standard EPI-sequences. 
The postprocessing and calculation requires considerable 
caution to avoid misinterpretation, as explained in Section 
2. Appropriate theoretical models for the exact calculation 
of an AIF and the quantification of absolute perfusion 
parameters were recently suggested [18,23], but they 
have not yet been validated in clinical studies. Perfusion 
imaging is a very powerful method that provides unique 
information to supplement and improve our understanding 
of brain inflammation. It is a potential tool for predicting 
acute lesion formation and might serve as a valuable 
imaging technique in monitoring the effects of novel 
treatments. 
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